InsuLife’s Clinical Development R&D Activities Receives Approval From SKATTEFUNN
October 15, 2020
The SkatteFUNN funding scheme from the Research Council of Norway has been approved for our Clinical Development Project spanning R&D activities for the period 2020-2022.
Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental Levellor™ spray-based insulin to market.
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
